The pathophysiological cellular phenotypes of genetically heritable heart diseases can be modeled using disease-specific human induced pluripotent stem cell cardiomyocyte (hiPSC-CM). Modeling enables broader understanding of the mechanisms leading to compromised electrical and contractile coupling.
Genetically engineered animal models have historically been used to model human diseases. However, there are valid concerns with the predictivity of these studies and translational potential to human conditions. Patient derived hiPSC-Cardiomyocytes provide an excellent model system to understand the underlying causes of these cardiomyopathies and can be potentially used for drug screening. The xCELLigence Cardio and CardioECR systems capture the integrated functional activity of cardiomyocytes. The data enable the assessment of cardiac disease models and for the screening of potential therapeutics to remedy the disease phenotype.
New Scientific statement from American Heart Association on hiPSCs published in Circulation; Genomics and Precision Medicine
In this video, Dr. Jason Maynes, Principal Investigator at the Hospital for Sick Children in Toronto, Canada, describes using the xCELLigence RTCA CardioECR system to simultaneously analyze the function (contractility) and ion channel activity of diseased pediatric iPSC cardiomyocytes.
The contractile and electrical activities of LMNA and CTRL cardiomyocytes were evaluated 12 days post-seeding, when the cells generated consistent and robust contractile and electrical signals. The data presented in the table was mean ± STDEV; N=24. BRa: Beating Rate B; Ampb: Beating Amplitude; **: P<0.01; FPDc: FPD values were obtained while LMNA and CTRL cardiomyocytes were electrically paced at 1 Hz.
Simplify your workflow. No cell labeling required. Simply seed your cells, monitor, and evaluate the mechanism, efficacy, or toxicity response of pharmaceutical drugs in cardiomyocytes.
The CardioECR is used to assess the functional differences relating to cell growth and viability, contractility, and electrophysiology of diseased iPSC-CM cells, providing a method to identify unique disease-related phenotypes.
Using the Agilent xCELLigence RTCA ePacer for Functional Maturation of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Interested in learning more? Request a demo by clicking below.
Precision Health Resource of Control iPSC Lines for Versatile Multilineage Differentiation.
Hildebrandt MR, Reuter MS, Wei W, Tayebi N, Liu J, Sharmin S, Mulder J, Lesperance LS, Brauer PM, Mok RSF, Kinnear C, Piekna A, Romm A, Howe J, Pasceri P, Meng G, Rozycki M, Rodrigues DC, Martinez EC, Szego MJ, Zúñiga-Pflücker JC, Anderson MK, Prescott SA, Rosenblum ND, Kamath BM, Mital S, Scherer SW, Ellis J. Stem Cell Reports. 2019 Dec 10;13(6):1126-1141. (The Hospital for Sick Children, Canada)
Parabolic, Flight-Induced, Acute Hypergravity and Microgravity Effects on the Beating Rate of Human Cardiomyocytes.
Acharya A, Brungs S, Lichterfeld Y, Hescheler J, Hemmersbach R, Boeuf H, Sachinidis A. Cells. 2019 Apr 14;8(4). pii: E352. (University of Cologne, Germany)
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as Models for Cardiac Channelopathies: A Primer for Non-Electrophysiologists.
Priyanka Garg, Vivek Garg, Rajani Shrestha, Michael C. Sanguinetti, Timothy J. Kamp and Joseph C. Wu. Circ Res. 2018 Jul 6;123(2):224-243. (Stanford Cardiovascular Institute, USA)
MLP and CARP are linked to chronic PKCα signalling in dilated cardiomyopathy.
Lange S, Gehmlich K, Lun AS, Blondelle J, Hooper C, Dalton ND, Alvarez EA, Zhang X, Bang ML, Abassi YA, Dos Remedios CG, Peterson KL, Chen J, Ehler E. Nat Commun. 2016 Jun 29;7:12120. (University of California, San Diego. USA)
Integrin-linked kinase mediates force transduction in cardiomyocytes by modulating SERCA2a/PLN function.
Traister A, Li M, Aafaqi S, Lu M, Arab S, Radisic M, Gross G, Guido F, Sherret J, Verma S, Slorach C, Mertens L, Hui W, Roy A, Delgado-Olguín P, Hannigan G, Maynes JT, Coles JG. Nat Commun. 2014 Sep 11;5:4533. (Hospital for Sick Children, Canada)
Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells.
Han L, Li Y, Tchao J, Kaplan AD, Lin B, Li Y, Mich-Basso J, Lis A, Hassan N, London B, Bett GC, Tobita K, Rasmusson RL, Yang L. Cardiovasc Res. 2014 Nov 1;104(2):258-69. (University of Pittsburgh School of Medicine, USA)
For Research Use Only. Not for use in diagnostic procedures.
RA44671.6521643518